Latest Filings

Issuer Activity

Insider Overview :: Stem Cell Therapeutics Corp. (T:SSS) [?]
Business Focus: Biopharmaceuticals Share on StockTwits
Recent Price for SSS
CAD 0.380 +0.01 (+1.33%)
TSX Delayed 15 minutes
Apr 24 1417 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
0.390 0.740 N/A 130,107 76.86
1-Day Low 52-Week Low Yield Avg. Volume  
0.370 0.140 0.0% 218,405  
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for SSS within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 23rd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 21/14 Apr 17/14 Uger, Robert Direct Ownership Options 50 - Grant of options 1,262,013  
Apr 21/14 Apr 17/14 Petrova, Penka Direct Ownership Options 50 - Grant of options 782,711  
Apr 21/14 Apr 17/14 Stiernholm, Bjorn Johan Niclas Direct Ownership Options 50 - Grant of options 4,793,025  
Apr 21/14 Apr 17/14 Parsons, James Todd Direct Ownership Options 50 - Grant of options 1,086,119  
Apr 15/14 Mar 10/14 Reynolds, Thomas Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Mar 17/14 Mar 10/14 Beshar, Luke Direct Ownership Options 50 - Grant of options 200,000  
Mar 17/14 Mar 10/14 Beshar, Luke Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Apr 15/14 Mar 6/14 Reynolds, Thomas Direct Ownership Options 50 - Grant of options 200,000  
Feb 12/14 Jan 29/14 Kirkman, Robert Lawrence Direct Ownership Options 50 - Grant of options 200,000  
Jan 17/14 Jan 17/14 Stiller, Calvin R. Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.620
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for SSS within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 23rd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 21/14 Apr 17/14 Uger, Robert Direct Ownership Options 50 - Grant of options 1,262,013  
Apr 21/14 Apr 17/14 Petrova, Penka Direct Ownership Options 50 - Grant of options 782,711  
Apr 21/14 Apr 17/14 Stiernholm, Bjorn Johan Niclas Direct Ownership Options 50 - Grant of options 4,793,025  
Apr 21/14 Apr 17/14 Parsons, James Todd Direct Ownership Options 50 - Grant of options 1,086,119  
Apr 15/14 Mar 6/14 Reynolds, Thomas Direct Ownership Options 50 - Grant of options 200,000  
Apr 15/14 Mar 10/14 Reynolds, Thomas Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Mar 17/14 Mar 10/14 Beshar, Luke Direct Ownership Options 50 - Grant of options 200,000  
Mar 17/14 Mar 10/14 Beshar, Luke Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Feb 12/14 Jan 29/14 Kirkman, Robert Lawrence Direct Ownership Options 50 - Grant of options 200,000  
Feb 12/14 Dec 17/13 Kirkman, Robert Lawrence Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for SSS on April 23, 2014 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Calvin R. Stiller
Independent Chairman of the Board
Niclas Stiernholm
President, Chief Executive Officer, Director
James T. Parsons
Chief Financial Officer
Bob Uger
Chief Scientific Officer
Penka Petrova
Vice President - Drug Development
Scott Duncan
Director - Intellectual Property
Company Contact
Address: 96 Skyway Avenue
TORONTO ON M9W 4Y9
Tel: 1-416-5950627
Website: www.stemcellthera.com
IR: www.stemcellthera.com/IR.aspx?section=stockinfo
Business Overview
Stem Cell Therapeutics Corp. (SCT) is a Canada-based biopharmaceutical company engaged in advancing cancer stem cell discoveries into cancer therapies. SCT's clinical stage programs include the tigecycline program, which is being evaluated in a multi-centre Phase I study in patients with Acute Myeloid Leukemia (AML), as well as TTI-1612, a non-stem cell asset being tested in a 28-patient Phase I trial in interstitial cystitis (IC) patients. The Company also has two preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tum
Financial Overview
For the nine months ended 30 September 2013, Stem Cell Therapeutics Corp revenues was not reported. Net loss increased from C$1.1M to C$3M. Higher net loss reflects Research & Develolpment Costs increase from C$734K to C$1.9M (expense), Amortization of intangible assets(1) increase from C$2K to C$412K (expense), Stock-based compensation increase from C$4K (income) to C$92K (expense).
Employees: 7 as of Dec 31, 2008
Reporting Currency: Canadian Dollars
Enterprise value: $45.27M as of Dec 31, 2013
Annual revenue (TTM): $0.00M as of Dec 31, 2013
EBITDA (TTM): -$2.61M as of Dec 31, 2013
Net annual income (TTM): -$3.02M as of Dec 31, 2013
Free cash flow (TTM): -$1.68M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 202,272,196 as of Apr 7, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
ProMetic Life Sciences (T:PLI)
Cardiome Pharma (T:COM)
 
Stem Cell Therapeutics Corp. Insider Report Only $20.00